News Medexus Pharmaceuticals Inc.

Equities

MDP

CA58410Q2036

Market Closed - Toronto S.E. Other stock markets 01:29:59 08/05/2024 am IST			5-day change	1st Jan Change
1.77 ^CAD	+0.57%		-2.75%	-28.34%

26/03	Medexus Pharmaceuticals Announces US Food and Drug Administration Approves It's Supplemental Biologics License Application for IXINITY(R)	CI
09/02	Medexus Pharmaceuticals Maintained at Speculative Buy at Stifel GMP After Fiscal Q3 Miss; Price Target Cut to C$2.85	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Federal Court Finds Patent For Concentrated Methotrexate Solutions Obvious	07/05	AQ
Medexus Concludes Metoject Litigation, Patent No Longer in Effect in Canada	02/05	NE
Medexus to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference	02/04	NE
FDA Approves Medexus's Supplemental Biologics License Application for IXINITY to Treat Hemophilia B in Pediatric Patients	27/03	AQ
Medexus Pharmaceuticals Announces US Food and Drug Administration Approves It's Supplemental Biologics License Application for IXINITY(R)	26/03	CI
FDA Approves Medexus's Supplemental Biologics License Application for IXINITY(R) to Treat Hemophilia B in Pediatric Patients	26/03	NE
Medexus Pharmaceuticals Maintained at Speculative Buy at Stifel GMP After Fiscal Q3 Miss; Price Target Cut to C$2.85	09/02	MT
Medexus Pharmaceuticals Down 30% After Announces Fiscal Q3 2024 Results	09/02	MT
Medexus Pharmaceuticals Announces Fiscal Q3 2024 Results	08/02	MT
Transcript : Medexus Pharmaceuticals Inc., Q3 2024 Earnings Call, Feb 08, 2024	08/02
Medexus Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	08/02	CI
Medexus Announces Fiscal Q3 2024 Results	08/02	NE
North American Morning Briefing : Stock Futures Hold Line Ahead of More Earnings, Fedspeak	07/02	DJ
Medexus Schedules Third Fiscal Quarter 2024 Conference Call	30/01	NE
Medexus Pharmaceuticals - Health Canada Accepts for Review Medexus's New Drug Submission for Topical Terbinafine	09/01	AQ
Medexus Pharmaceuticals Says Health Canada to Review New Drug Submission for Topical Terbinafine	08/01	MT
Medexus Pharmaceuticals Announces Health Canada Accepts for Review Medexus's New Drug Submission, or NDS, for Terbinafine Hydrochloride Nail Lacquer to Treat fungal N Infections	08/01	CI
Health Canada Accepts for Review Medexus's New Drug Submission for Topical Terbinafine	08/01	NE
Transcript : Medexus Pharmaceuticals Inc., Q2 2024 Earnings Call, Nov 09, 2023	09/11
Medexus Announces Strong Fiscal Q2 2024 Results, Including Quarterly Revenue of US$30.3 Million	09/11	NE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Medexus Pharmaceuticals Inc.

Equities

MDP

CA58410Q2036

Summary

Filters